TNFSF10 and cardiomyopathy: In a diabetic mouse model, direct administration of TRAIL reduced development of cardiomyopathy [26] and another similar study in diabetic mice demonstrated that systemic TRAIL delivery exhibited antiatherosclerotic activity [27].